Welcome to our dedicated page for SHL Telemed news (Ticker: SHLT), a resource for investors and traders seeking the latest updates and insights on SHL Telemed stock.
SHL Telemedicine Ltd. develops and markets personal telemedicine systems and provides medical call center services for cardiovascular and related diseases. Its recurring company updates center on SmartHeart®, a portable 12-lead ECG platform used for at-home and mobile cardiovascular assessment, along with subscriber-based telemedicine services that use telephone and internet communications.
News about SHL Telemedicine also covers direct-to-consumer cardiac care offerings, cardiologist-reviewed ECG workflows, at-home biomarker blood testing in Israel, healthcare partnerships, clinical study results, military and mobile-care deployments, regional operating results and leadership or governance updates. The company is listed on Nasdaq under SHLT and on the SIX Swiss Exchange under SHLTN.
DocGo (NASDAQ: DCGO) has expanded its partnership with SHL Telemedicine to integrate SmartHeart® portable 12-lead ECG devices across its mobile health care units nationwide, following initial deployment in the New York-New Jersey area. The collaboration aims to address the critical gap in cardiovascular care access, noting that 46% of U.S. counties lack cardiologists according to the Journal of the American College of Cardiology.
The partnership will enable high-quality ECG screenings in patients' homes and underserved communities, with cardiologist-reviewed results available promptly. The first phase of expansion will target California, focusing on rural communities and healthcare deserts. This initiative aims to improve patient outcomes while reducing emergency room visits and overall healthcare costs.
SHL Telemedicine (NASDAQ: SHLT, SIX: SHLTN) has appointed David Arnon as its new CEO, effective August 6, 2024. Arnon, with over 17 years of experience in the healthcare insurance industry, will succeed Erez Nachtomy. He brings extensive expertise in sales, marketing, and operations, particularly in the Israeli healthcare sector.
Arnon's previous roles include CEO of DORAL MEA, Deputy CEO at Clal Insurance and Finance, and various executive positions at Harel Insurance Investments. The appointment aims to leverage his leadership skills to drive innovation, expand offerings, and strengthen SHL's global market presence in telemedicine solutions.
SHL Telemedicine, a premier developer of personal telemedicine solutions, announced it is in discussions with Discount Capital, the investment arm of Israel Discount Bank, for a potential investment in SHL's Israeli operations. Currently, no decisions or binding agreements have been made. SHL assures to update the market as necessary.
SHL Telemedicine has unveiled a revolutionary at-home Biomarker blood test in Israel, enhancing their suite of telemedicine solutions. This test, guided by SHL’s medical team, follows a 12-lead ECG and aims to rapidly identify cardiac markers indicative of a heart attack. Results are available within ten minutes. SHL integrates this new test with anamnesis and ECG broadcasting, providing comprehensive cardiac diagnostics from home, which can significantly speed up heart attack diagnosis and improve patient outcomes. This innovation marks a significant step forward in accessible cardiac care.
SHL Telemedicine has officially launched its SmartHeart® membership program in the US, following a successful soft launch in November 2023. This program provides a revolutionary at-home 12-lead ECG service, complete with 24/7 cardiologist reviews and telehealth consultations. The soft launch exceeded expectations, demonstrating substantial demand and positive feedback. Recent clinical studies with Imperial College London showed significant reductions in hospital readmissions and emergency visits among post-ACS patients using SmartHeart®. The membership aims to empower users to manage their heart health proactively with a portable ECG device, expert analysis, and telehealth services.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.